Flag of the European Union EU Clinical Trials Register Help

Clinical trials for System

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44356   clinical trials with a EudraCT protocol, of which   7382   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    9,803 result(s) found for: System. Displaying page 130 of 491.
    «« First « Previous 126  127  128  129  130  131  132  133  134  Next» Last»»
    EudraCT Number: 2019-000781-38 Sponsor Protocol Number: sempa1 Start Date*: 2019-05-07
    Sponsor Name:Aarhus University Hospital
    Full Title: Effect of Empagliflozin and Semaglutide on Cardio-Renal Target Organ Damage in patients with type 2 diabetes – A randomized Trial
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2022-004102-29 Sponsor Protocol Number: 18922A Start Date*: 2023-03-03
    Sponsor Name:H. Lundbeck A/S
    Full Title: An open-label, single-dose, pharmacokinetic study to evaluate IV eptinezumab in children and adolescents with migraine, followed by an optional, multiple-dose, open-label extension period
    Medical condition: Migraine in children and adolescents Migraine
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10027599 Migraine PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2020-004536-22 Sponsor Protocol Number: EPIC2020 Start Date*: 2020-12-08
    Sponsor Name:Ole Thorlacius-Ussing
    Full Title: A phase II Study of Electroporation Potentiated Immunotherapy in Liver Metastatic Pancreatic Cancer
    Medical condition: Metastatic pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10033605 Pancreatic cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-001393-34 Sponsor Protocol Number: MNILCAPS001 Start Date*: 2014-04-14
    Sponsor Name:UZ Leuven
    Full Title: Ilaris® (canakinumab) efficacy and safety in CAPS patients without confirmed mutation on exon 3 of gene CIAS1 and young (<2yrs) CAPS patients with severe neurological (CINCA) phenotype.
    Medical condition: Cryopyrin-Associated Periodic Syndromes
    Disease: Version SOC Term Classification Code Term Level
    17.1 10010331 - Congenital, familial and genetic disorders 10068850 Cryopyrin associated periodic syndrome PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-002810-15 Sponsor Protocol Number: CHUB-Neuro-ENMG-MS Start Date*: 2021-06-25
    Sponsor Name:CHU Brugmann
    Full Title: Peripheral neuropathy as potential side effect in patients with multiple sclerosis treated with teriflunomide.
    Medical condition: Multiple sclerosis, treated with teriflunomide
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2013-002825-52 Sponsor Protocol Number: CRAD001A2401T Start Date*: 2014-04-03
    Sponsor Name:Medizinische Hochschule Hannover
    Full Title: Single-center, open-label, single-arm Phase IIa study in kidney transplant patients with acute T-cell-mediated rejection in renal transplant according to Banff criteria (class IA and IB) without (s...
    Medical condition: Acute cellular rejection after kidney transplantation
    Disease: Version SOC Term Classification Code Term Level
    16.1 10021428 - Immune system disorders 10023439 Kidney transplant rejection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-003027-11 Sponsor Protocol Number: DURWIN Start Date*: 2019-05-16
    Sponsor Name:CONSORZIO ONCOTECH
    Full Title: A prospective, multi-center, open-label, single-arm, two- step phase II study of DURvalumab (MEDI4736) in patients WIth poor performance status as first-liNe treatment for advanced urothelial cance...
    Medical condition: Patients aged 18 years or older with histologically or cytologically documented locally advanced (on the TNM staging system, T4b and any N; or any T and N2–3) or metastatic (M1, stage IV) urothelia...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10064467 Urothelial carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-002382-30 Sponsor Protocol Number: RDD677 Start Date*: 2015-03-13
    Sponsor Name:The Clatterbridge Cancer Centre NHS Foundation Trust
    Full Title: Phase II study of neoadjuvant cisplatin and gemcitabine chemotherapy versus upfront surgery in patients with resectable proximal biliary tract cancer:
    Medical condition: Resectable Biliary Tract Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017621 Gallbladder carcinoma localized LLT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008593 Cholangiocarcinoma PT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10034446 Periampullary carcinoma resectable LLT
    Population Age: Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2012-001708-39 Sponsor Protocol Number: S54224 Start Date*: 2012-06-07
    Sponsor Name:University Hospital Leuven
    Full Title: Prospective randomized trial concerning three different stimulation methods in IVF/ICSI treatment in poor responders
    Medical condition: Subfertility
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038604 - Reproductive system and breast disorders 10016465 Fertility female decreased LLT
    14.1 10038604 - Reproductive system and breast disorders 10016398 Female infertility LLT
    Population Age: Adults Gender: Female
    Trial protocol: BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-002571-18 Sponsor Protocol Number: 170KG18 Start Date*: 2019-07-22
    Sponsor Name:University Medical Center Groningen
    Full Title: EFFECT OF FERRIC CARBOXYMALTOSE ON EXERCISE CAPACITY AFTER KIDNEY TRANSPLANTATION: A MULTICENTER RANDOMIZED CONTROLLED TRIAL
    Medical condition: Iron deficiency in kidney transplant recipients
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004861 10022971 Iron deficiencies HLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-004392-12 Sponsor Protocol Number: CIDP04 Start Date*: 2019-11-20
    Sponsor Name:UCB Biopharma SPRL
    Full Title: An Open-Label Extension Study to Investigate the Long-Term Safety, Tolerability, and Efficacy of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
    Medical condition: Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10057645 Chronic inflammatory demyelinating polyradiculoneuropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) FR (Completed) BE (Completed) ES (Restarted) NL (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2016-002411-17 Sponsor Protocol Number: CIDP01 Start Date*: 2019-04-29
    Sponsor Name:UCB Biopharma SRL
    Full Title: A Multicenter, Randomized, Subject-Blind, Investigator-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy, Safety, and Tolerability of Rozanolixizumab in Subjects with Chronic ...
    Medical condition: Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10057645 Chronic inflammatory demyelinating polyradiculoneuropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DK (Completed) NL (Completed) DE (Completed) ES (Completed) FR (Completed) GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2020-001045-39 Sponsor Protocol Number: CT-P43_3.1 Start Date*: 2020-11-12
    Sponsor Name:Celltrion, Inc
    Full Title: A Randomized, Active-Controlled, Double-Blind, Phase 3 Study to Compare the Efficacy and Safety of CT-P43 to Stelara in Patients with Moderate to Severe Plaque Psoriasis
    Medical condition: Moderate to Severe Plaque Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed)
    Trial results: View results
    EudraCT Number: 2016-001166-29 Sponsor Protocol Number: inims-009 Start Date*: 2020-03-18
    Sponsor Name:University Medical Centre Hamburg-Eppendorf
    Full Title: A randomised controlled trial to compare ocrelizumab or alemtuzumab with autologous hematopoietic stem cell transplantation (aHSCT) in high inflammatory multiple sclerosis (COAST)
    Medical condition: relapsing-remitting multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-001036-25 Sponsor Protocol Number: UNI91103-201 Start Date*: 2021-06-01
    Sponsor Name:UNION therapeutics A/S
    Full Title: A RANDOMIZED PLACEBO-CONTROLLED PHASE 2 STUDY TO ASSESS THE SAFETY AND EFFICACY OF UNI91103 INTRANASAL ADMINISTRATION IN ADULTS WITH ASYMPTOMATIC OR MILDLY SYMPTOMATIC COVID-19
    Medical condition: Covid-19
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004862 10084401 COVID-19 respiratory infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-006012-24 Sponsor Protocol Number: NBI-827104-ET2016 Start Date*: 2021-04-06
    Sponsor Name:Neurocrine Biosciences
    Full Title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of NBI-827104 in Subjects with Essential Tremor
    Medical condition: Essential tremor
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10015496 Essential tremor PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2014-004086-24 Sponsor Protocol Number: AIO-PAK-0114 Start Date*: 2015-11-18
    Sponsor Name:AIO-Studien-gGmbH
    Full Title: Induction Treatment with nab-Paclitaxel/Gemcitabine for First-line Treatment of Metastatic Pancreatic Cancer Followed by Either Alternating Application of Gemcitabine Monotherapy and nab-Paclitaxel...
    Medical condition: metastatic pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10033605 Pancreatic cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-002693-10 Sponsor Protocol Number: VAC3_SARS-CoV2_seroconversion_study Start Date*: 2021-07-15
    Sponsor Name:Medical University of Vienna, Department for Internal Medicine III, Division of Rheumatology
    Full Title: A Phase II Study to Evaluate Safety and Efficacy to a Third Vaccination in Immunocompromised Patients with Inadequate Humoral Response after Primary mRNA SARS-CoV-2 (Covid-19) Vaccination
    Medical condition: Vaccination against SARS-CoV-2 in patients with immunosuppressive therapy or immunodeficiencies
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-006044-14 Sponsor Protocol Number: EB05-04-2020 Start Date*: 2021-10-25
    Sponsor Name:Edesa Biotech Research Inc.
    Full Title: A randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of EB05 + SOC vs. placebo + SOC in adult hospitalized patients with COVID19
    Medical condition: SARS-CoV-2 Positive Pneumonia - level 3-7 in the nine-point COVID-19 severity scale:
    Disease: Version SOC Term Classification Code Term Level
    23.1 10021881 - Infections and infestations 10084380 COVID-19 pneumonia PT
    23.1 10021881 - Infections and infestations 10084383 Novel COVID-19-infected pneumonia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-000732-54 Sponsor Protocol Number: NCH-201803 Start Date*: 2021-10-11
    Sponsor Name:Rheinische Friedrich-Wilhelms-Universität Bonn
    Full Title: FINISHER - Fight Inflammation to Improve outcome after aneurysmal Subarachnoid Hemorrhage
    Medical condition: aneurysmal subarachnoid hemorrhage
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10042316 Subarachnoid haemorrhage PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 126  127  128  129  130  131  132  133  134  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Aug 22 21:45:02 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA